The Company determines the fair value of share-based payments on the date of grant using the Black-Scholes option pricing model in accordance with ASC Topic 718, which requires assumptions regarding the risk-free interest rate, the expected life of the awards, expected volatility over the term of the awards, and expected dividends. No stock options were granted during the three and six months ended June 30, 2026 or 2025.

A summary of the stock option activity under the Company’s plans for the six months ended June 30, 2026, is as follows:

	Number of shares			Weighted average exercise price
Options outstanding at beginning of year		19,716		$	35.33
Granted		—			—
Less:
Exercised		—			—
Forfeited prior to vesting		—			—
Canceled or expired		(14,215	)		12.58
Options outstanding at June 30, 2026		5,501			96.60
Options exercisable at end of June 30, 2026		5,501		$	96.60

All outstanding options were fully vested and exercisable as of June 30, 2026, and had no aggregate intrinsic value as the exercise price exceeded the market price of the Company's common stock. As of June 30, 2026, total remaining unrecognized compensation cost related to non-vested stock options, net of forfeitures, was $0.

	Three months ended June 30,					Six months ended June 30,
	2026		2025			2026		2025
Cost of goods sold	$	—	$	1		$	—	$	1
Sales and marketing		—		(1	)		—		—
Research and product development		—		3			—		7
General and administrative		—		18			—		36
	$	—	$	21		$	—	$	44

On July 17, 2026, the Board of Directors adopted the Company's 2026 Omnibus Incentive Plan. No awards had been granted under the plan as of the date of this report. See Note 14 — Subsequent Events.